FDA calendar · July 2023 · built from SEC filings

PDUFA dates July 2023: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

1 PDUFA date fell in July 2023: LYMPHIR (July 28). The FDA calendar also recorded 31 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in July 2023

1 PDUFA target action date in July 2023, soonest first, each linked to the SEC filing or FDA page that disclosed it. Data as of .
PDUFA dateCompanyTickerDrugIndicationSource
July 28, 2023CITIUS ONCOLOGY, INC.CTORLYMPHIRSEC Form 10-K, filed 2024-12-27

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

July 2023: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Jul 2023Month disclosedVYGLXIA (troriluzole)BHVNNDA/BLA submission—CompletedSEC Form 10-K
Jul 2023Month disclosedYUSIMRYCHRSFDA approval—ApprovedSEC 8-K Exhibit 99.1
Jul 2023Month disclosed—CTXRComplete Response Letter—CRL issuedSEC Form 10-K
Jul 2023Month disclosedCYFENDUSEBSFDA approval—ApprovedSEC 8-K Exhibit 99.1
Jul 2023Month disclosedYUTREPIA (treprostinil)LQDANDA/BLA submission—CompletedSEC Form 10-K
Jul 2023Month disclosedHETLIOZ® (tasimelteon)VNDANDA/BLA accepted—CompletedSEC Form 10-K
July 13, 2023Veklury (remdesivir)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
July 17, 2023Beyfortus (nirsevimab-alip)AZNFDA approvalTo prevent respiratory syncytial virus (RSV) lower respiratory tract diseasePress ReleaseApprovedFDA Novel Drug Approvals
July 20, 2023Otezla (apremilast)AMGNLabel expansion—ApprovedopenFDA Drugs@FDA
July 21, 2023Wegovy (semaglutide)NVOLabel expansion—ApprovedopenFDA Drugs@FDA
July 21, 2023YCANTH (cantharidin)VRCAFDA approvalmolluscum contagiosum and began capitalizing inventory purchases of saleable productApprovedSEC 8-K Exhibit 99.1
July 24, 2023Xdemvy (lotilaner)TARSFDA approvalTo treat Demodex blepharitisApprovedFDA Novel Drug Approvals
July 27, 2023Nesina (alogliptin benzoate)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
July 27, 2023Kazano (alogliptin benzoate; metformin hydrochloride)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
July 28, 2023Lymphir (denileukin diftitox-cxdl)CTXRComplete Response Letter—CRL issuedFDA Complete Response Letters
July 29, 2023LYMPHIRCTORComplete Response Letter—CRL issuedsec_424b
July 31, 2023Jemperli (dostarlimab-gxly)GSKLabel expansion—ApprovedopenFDA Drugs@FDA

July 2023: dated readouts

DateDrugCompanyEventIndicationStatusSource
Jul 2023Month disclosedsabirnetug (ACU193)ABOSTopline readout—Met primary endpointSEC Form 10-Q
Jul 2023Month disclosedVyvgart (efgartigimod alfa)ARGXTopline readout—PositiveSEC 8-K Exhibit 99.1
Jul 2023Month disclosedICOTYDE (icotrokinra)PTGXTopline readout—PositiveSEC Form 10-K
Jul 2023Month disclosed—VXRTInterim readout—Met primary endpointSEC Form 10-Q

July 2023: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Jul 2023Month disclosedtinlarebant (LBS-008)BLTETrial startGA associated with dry AMDCompletedSEC Form 10-K
Jul 2023Month disclosedAMP-518AIMTrial startpost-COVID conditionsCompletedsec_s1
Jul 2023Month disclosedPovofortay (povorcitinib)INCYTrial startmoderate to severe uncontrolled asthmaCompletedSEC Form 10-Q
Jul 2023Month disclosedTLX250TLXTrial startdiverse range of solid tumors for potential therapeutic and diagnostic applicationsCompletedSEC 8-K Exhibit 99.1
Jul 2023Month disclosedAJ201ATXITrial start—CompletedSEC Form 10-K
Jul 2023Month disclosedHMPL-415HCMTrial startadvanced malignant solid tumorsCompletedSEC Form 10-K
Jul 2023Month disclosedbispecific (INCA33890)INCYTrial startselect advanced solid tumorsCompletedSEC Form 10-Q
Jul 2023Month disclosedKB407KRYSTrial startCF, regardless of their underlying genotypeCompletedSEC Form 10-Q
Jul 2023Month disclosedACI-7104ACIUTrial start—CompletedSEC 8-K Exhibit 99.1
Jul 2023Month disclosedvopimetostat (TNG462)TNGXTrial start—CompletedSEC Form 10-K

Questions

What PDUFA dates are in July 2023?

1 PDUFA date fell in July 2023: LYMPHIR (July 28). The FDA calendar also recorded 31 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.